ABBV AbbVie Inc

By Colin Kellaher

AbbVie Inc. (ABBV) on Thursday said a phase 3 study of Rinvoq in psoriatic arthritis met its primary and all ranked secondary endpoints.

The North Chicago, Ill., biopharmaceutical company said both doses of Rinvoq met the primary endpoint of ACR20 response at week 12 versus placebo in adults with active psoriatic arthritis who have responded inadequately to one or more biologic disease modifying anti-rheumatic drugs.

AbbVie said patients on both doses also achieved significantly greater responses compared with placebo for all ranked secondary endpoints.

AbbVie said the study data will support regulatory submissions for Rinvoq in psoriatic arthritis, a chronic disease characterized by joint inflammation and the skin lesions associated with psoriasis.

The U.S. Food and Drug Administration earlier this year approved Rinvoq for adults with moderately to severely active rheumatoid arthritis.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

October 31, 2019 09:13 ET (13:13 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.